Next week, US voters will take to the polling booths to decide who will be the next President of the US. Will Donald Trump win a second term? Or will Joe Biden and the Democrats take power? And what will the result mean for the pharmaceutical industry? Deputy Editor of The Medicine Maker, James Strachan, explores these issues and looks back at Trump’s first tenure.

 

And in the spirit of Halloween, this week’s newsletter also features research into how compounds derived from spider venom could help with managing pain.

Stephanie Sutton, Editor
 
TRENDS & FORECASTS
The Battle for the Future of American Healthcare
10/26/2020 | James Strachan
Looking back at Trump’s tenure, and the potential implications of the US elections for pharma and the Affordable Health Act.
DRUG DISCOVERY
Poisoning Pain
10/28/2020 | Maryam Mahdi
Exploring a new approach to treating IBS pain.
BUSINESS PRACTICE
Crisis Point
10/23/2020 | Maryam Mahdi
How is African pharma coping with the COVID-19 pandemic?
BUSINESS PRACTICE
Harnessing Dark Data
10/24/2020 | Graeme Dennis
Graeme Dennis questions why the industry refuses to make use of the significant amount of data it generates.
 
Webinars
Interested in AAV-based gene therapies?

Don’t miss our three-part educational webinar series with Cytiva that covers modern plasmid and AAV production for gene therapy applications. Find out more
Expand Your Operations Without Astronomical Costs!

Multimodal suites can help you shift your operations as technologies change, business expands, and patient needs evolve. Don’t miss our upcoming webinar with CRB’s SlateXpace on November 11, 2020. Find out more
 
White Papers
New white paper: The optimal immune monitoring technology for your study

Get real-world insights into the practical applications of the 6 leading immune monitoring technologies. Includes guidelines and answers to clinical leaders’ most pressing questions. Download Now 
Exploring the rigor and requirements of Analytical Quality by Design

Analytical QbD (AQbD) promises to extend the rigor and benefits of QbD into the area of analytical method development. Read more
Top five ways of improving the stability of your formulation

Formulation development is a critical activity for many industries, from pharmaceuticals, to paints and coatings. Read more
 
Special Promotions
What is the Multi-Attribute Method?

Multi-Attribute Method harnesses the power of high-resolution accurate mass-MS to support bioprocess optimization. Endorsed by regulators, the approach is now being used by medicine makers worldwide. Read more
The Cell + Gene Curator - a newsletter focused on the science of cell and gene therapies

Connecting you to discoveries, innovation, and business updates from the cell and gene therapy community. Learn more and subscribe
 
Must-See Events Worldwide

We work with event organizers from all around the world to help bring the pharma industry together, from large congresses to intimate meetings that fit around a table. Discover some of the events that we partner with and and stay up-to-date with the latest developments.
Find out more
This email was sent to {~email~} by info@themedicinemaker.com. To ensure delivery of emails to your inbox, please add info@themedicinemaker.com to your address book or safe sender list. To view online, please click here.

Create or manage your account here
Unsubscribe here

The Medicine Maker is a brand of Texere Publishing Limited (trading as Conexiant)

Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.